4686-98-0

Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIETHOXYBENZALDEHYDE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic benefits.
Used in Organic Synthesis:
In the field of organic chemistry, 2,5-DIETHOXYBENZALDEHYDE is utilized as a building block for the creation of diverse organic compounds, leveraging its reactive aldehyde group and ethoxy substituents.
Used in Therapeutic Applications:
2,5-DIETHOXYBENZALDEHYDE is considered for its potential use as an anti-inflammatory and analgesic agent, due to its capacity to modulate biological responses and alleviate pain and inflammation.
Used in Neurodegenerative Disease Treatment:
2,5-DIETHOXYBENZALDEHYDE is being studied for its potential role in the treatment of neurodegenerative diseases, given its possible neuroprotective properties and ability to combat oxidative stress.
Used in Antioxidant Formulations:
2,5-DIETHOXYBENZALDEHYDE is also being explored for its potential as an antioxidant, which could be beneficial in various health and industrial applications where protection against oxidative damage is required.

InChI:InChI=1/C11H14O3/c1-3-13-10-5-6-11(14-4-2)9(7-10)8-12/h5-8H,3-4H2,1-2H3

Upstream product

• 74-90-8 hydrogen cyanide 
• 122-95-2 1,4-diethoxybenzene 
• 1194-98-5 2,5-Dihydroxybenzaldehyde 
• 75-03-6 ethyl iodide 
• 4885-02-3 Dichloromethyl methyl ether 
• 50-00-0 formaldehyd 
• 74-96-4 ethyl bromide 

Downstream Products

• 261789-10-0 2,5-diethoxyphenethylamine 
• 181305-38-4 1-(5-Bromo-pyridin-2-yl)-3-[2-(2,5-diethoxy-phenyl)-ethyl]-thiourea 
• 172366-04-0 4,7-diethoxy-1-methyleneindan 
• 172366-15-3 3-(2,5-diethoxyphenyl)propanoic acid 
• 172366-03-9 ethyl 3-(2,5-diethoxyphenyl)propanoate 
• 1027062-54-9 Benzyl-(5,8-diethoxy-3,4-dihydro-naphthalen-2-yl)-amine 
• 1026456-94-9 (2-Aminomethyl-5,8-diethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-benzyl-amine 
• 1026978-75-5 2-Benzylamino-5,8-diethoxy-1,2,3,4-tetrahydro-naphthalene-2-carbonitrile 
• 351002-98-7 2,5-diethoxybenzyl alcohol 

Relevant academic research and scientific papers

In vitro study and structure-activity relationship analysis of stilbenoid derivatives as powerful vasorelaxants: Discovery of new lead compound

The development of vasorelaxant as the antihypertensive drug is important as it produces a rapid and direct relaxation effect on the blood vessel muscles. Resveratrol (RV), as the most widely studied stilbenoid and the lead compound, inducing the excellent vasorelaxation effect through the multiple signalling pathways. In this study, the in vitro vascular response of the synthesized trans-stilbenoid derivatives, SB 1-8e were primarily evaluated by employing the phenylephrine (PE)-precontracted endothelium-intact isolated aortic rings. Herein we report trans-3,4,4′-trihydroxystilbene (SB 8b) exhibited surprisingly more than 2-fold improvement to the maximal relaxation (Rmax) of RV. This article also highlights the characterization of the aromatic protons in terms of their unique splitting patterns in 1H NMR.

Role of polar solvents for the synthesis of pillar[6]arenes

An efficient procedure for the synthesis of pillar[6]arenes has been developed. The procedure involves the condensation of 1,4-dialkoxybenzenes and paraformaldehyde in the presence of a catalytic amount of H2SO4 or BF3·OEt2 in polar solvent media (acetonitrile, ethyl alcohol, acetone etc.). In all cases the interaction afforded pillar[6]arenes in high yields.

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50's against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50's between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50's between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50's between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50's between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50's between 3 and 20 nM.

Anthracyclines

There is provided a novel method of synthesizing certain heterocyclic quinones. In particular there is provided a novel and regiospecific synthesis of 9-acetyl-6,11-dihydroxy-4-methoxy-7,8,9,10-tetrahydronaphthacene-5,12-quinone (7,9-dideoxydaunomycinone) which is a known intermediate in the synthesis of daunomycinone. There is also provided a method of preparing analogs of 7,9-dideoxydaunomycinone which thus provide for the preparation of known and desired analogs of daunomycinone. Daunomycinone is a known compound which is an intermediate in the preparation of the clinically accepted naturally-occurring antitumor antibiotics daunomycin and its derivative adriamycin.